A 8 weeks, randomized, double-blind, placebo-controlled human trial to evaluate the efficacy and safety of Angelica gigas N. extract powder(Nutragen) on immune enhancement

Jeonbuk National University Hospital0 个研究点目标入组 100 人开始时间: 待定最近更新: 2022年11月28日

适应症

试验速览

暂无简介。

•1) Male and female aged 19 or over and 75 or under at the screening examination
•2) Participants who had symptoms of upper respiratory infection (cold, tonsillitis, pharyngitis, laryngitis, sinusitis, otitis media, rhinitis, etc.) at least twice within 12 months before screening examination
•3) Participants who have fully understand the information provided about the study voluntarily decided to participate and agree to comply with precautions

•1) Patients who have received vaccination) within two months before ingestion date of investigational product
•2) Patients whose BMI is 18.5 kg/m2 under or 35 kg/m2 or over at the screening examination
•3) Patients who have clinically significant acute or chronic cardio-cerebrovascular systems, endocrine systems, immune systems, respiratory systems, hepatic biliary systems, kidneys and urinary systems, neuropsychiatric systems, musculoskeletal systems, inflammatory and hematologic and tumorigenic, gastrointestinal diseases, etc.
•4) Those who took medicines and health functional foods related to immunity enhancement within one month before the screening examination (refer to combination prohibited drugs)
•5) Patients with a history of significant hypersensitivity reaction to the ingredients of Angelica gigas
•6) Patients who have received anti-psychotic medication within three months before the screening examination
•7) Patients who have or are suspected of alcoholism or substance abuse
•8) Patients participated in another clinical trial within three months before the screening examination
•9) Patients who are judged ineligible to participate in the trial by the principal investigator for other reasons, including laboratory test outcomes

发起方